CPA
UTHR icon

Capital Performance Advisors’s United Therapeutics UTHR Stock Holding History

Capital Performance Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-564
Closed -$275K – 514
2025
Q4 		$275K Buy
+564
New +$263K 0.02% 330
2024
Q4 		– Sell
-229
Closed -$82.1K – 2569
2024
Q3 		$82.1K Buy
+229
New +$77.4K 0.03% 243

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Capital Performance Advisors's UTHR Position: Q1 2026 in Review

Capital Performance Advisors sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 564 shares — an estimated $275K sold.

Capital Performance Advisors first reported a position in UTHR in Q3 2024 and held it in 2 quarters. The position peaked at $275K in Q4 2025. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Capital Performance Advisors reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 564 United Therapeutics shares in Q1 2026, an estimated $275K.
  • Capital Performance Advisors first reported a position in United Therapeutics in Q3 2024 and held it in 2 quarters.
  • Capital Performance Advisors's United Therapeutics position peaked at $275K in Q4 2025.
  • 854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Capital Performance Advisors's 13F filing for Q1 2026, filed 7 May 2026.